Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Thumbnail

Judge sets 10-month deadline for e-cig makers to apply for federal approval

A federal judge has set a 10-month deadline, ending in May 2020, for e-cigarette and cigar makers to apply for FDA authorization to keep their products on the market.

Thumbnail

HIV elevates risk of heart failure, stroke

A large-scale study of people living with HIV has linked the immune deficiency to an increased risk of CVD, in particular heart failure and stroke.

Smokers 3 times more likely to die from CVD

Cigarette smokers are three times more likely than non-smokers to die from heart disease, an Australian study has found.

Thumbnail

Binge-watching TV threatens heart health

A study on the effect of different sedentary behaviors on CV health has pinned binge-watching television as a more harmful activity than sitting at a desk job, though the negative effects of both can potentially be reversed with exercise.

UTIs linked to 5 times the risk of ischemic stroke

Infections—most notably urinary tract infections—were linked to a significantly increased risk of acute ischemic stroke in a recent study out of the Icahn School of Medicine at Mount Sinai.

Thumbnail

San Francisco becomes 1st US city to ban e-cig sales

San Francisco will be the first city in the U.S. to ban the sale and distribution of e-cigarettes, NPR reported Tuesday—a significant move considering the nation’s biggest producer of e-cigs, Juul Labs, is based in the city.

Thumbnail

Testing underway for biodegradable CV implants

Researchers at Kazan Federal University in Russia are in the process of testing biodegradable plant-based implants that might one day replace artificial prostheses, eliminating the need for repeat surgeries as a patient’s vasculature evolves.

Thumbnail

FDA reaches vague conclusion in debate over safety of paclitaxel devices

Two days of debate over the safety of paclitaxel-coated and -eluting devices have culminated in a nonbinding recommendation by the FDA to continue sales of such devices for PAD patients, though the agency is also urging regulators to push for better long-term clinical data than is currently available.